BACKGROUND: Fear of disease progression (FOP) is a rational concern for women with Ovarian Cancer (OC) and depression is also common. To date there have been no randomized trials assessing the impact of psychological intervention on depression and FOP in this patient group. PATIENTS AND METHODS: Patients with primary or recurrent OC who had recently completed chemotherapy were eligible if they scored between 5 and 19 on the PHQ-9 depression and were randomized 1:1 to Intervention (3 standardized CBT-based sessions in the 6-12 weeks post-chemotherapy) or Control (standard of care). PHQ-9, FOP-Q-SF, EORTC QLQ C30 and OV28 questionnaires were then completed every 3 months for up to 2 years. The primary endpoint was change in PHQ-9 at 3 months....
BACKGROUND: Maintenance therapy induces remission and prolongs disease free interval in primary and ...
BACKGROUND: The aim of chemotherapy in patients with platinum resistant ovarian cancer is palliation...
Purpose: Women with advanced ovarian cancer generally have a poor prognosis but there is significant...
BACKGROUND: Fear of disease progression (FOP) is a rational concern for women with Ovarian Cancer (O...
Background: Fear of disease progression (FOP) is a rational concern for women with Ovarian Cancer (O...
From PubMed via Jisc Publications RouterHistory: received 2021-01-21, accepted 2021-05-22Publication...
Objective: The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate t...
This is the peer reviewed version of the following article: Howells, L., Hulbert-Williams, N. J. & B...
Approximately 21,550 women were diagnosed with Ovarian Cancer (OVCA) in 2009 and 14,600 died from th...
Chemotherapy for platinum-resistant/refractory ovarian cancer is motivated by the hope of benefit. W...
BACKGROUND: Most patients presenting with advanced ovarian cancer (AOC) eventually relapse. Symptom ...
PurposeGOG-259 was a 3-arm randomized controlled trial of two web-based symptom management intervent...
Objective The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate th...
BACKGROUND: Physical symptoms, anxiety, depression, fear of recurrence, sexual dysfunction, and soci...
Objective: This study investigated the fear of progression (FoP) in cancer patients and the discrimi...
BACKGROUND: Maintenance therapy induces remission and prolongs disease free interval in primary and ...
BACKGROUND: The aim of chemotherapy in patients with platinum resistant ovarian cancer is palliation...
Purpose: Women with advanced ovarian cancer generally have a poor prognosis but there is significant...
BACKGROUND: Fear of disease progression (FOP) is a rational concern for women with Ovarian Cancer (O...
Background: Fear of disease progression (FOP) is a rational concern for women with Ovarian Cancer (O...
From PubMed via Jisc Publications RouterHistory: received 2021-01-21, accepted 2021-05-22Publication...
Objective: The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate t...
This is the peer reviewed version of the following article: Howells, L., Hulbert-Williams, N. J. & B...
Approximately 21,550 women were diagnosed with Ovarian Cancer (OVCA) in 2009 and 14,600 died from th...
Chemotherapy for platinum-resistant/refractory ovarian cancer is motivated by the hope of benefit. W...
BACKGROUND: Most patients presenting with advanced ovarian cancer (AOC) eventually relapse. Symptom ...
PurposeGOG-259 was a 3-arm randomized controlled trial of two web-based symptom management intervent...
Objective The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate th...
BACKGROUND: Physical symptoms, anxiety, depression, fear of recurrence, sexual dysfunction, and soci...
Objective: This study investigated the fear of progression (FoP) in cancer patients and the discrimi...
BACKGROUND: Maintenance therapy induces remission and prolongs disease free interval in primary and ...
BACKGROUND: The aim of chemotherapy in patients with platinum resistant ovarian cancer is palliation...
Purpose: Women with advanced ovarian cancer generally have a poor prognosis but there is significant...